Harnessing the patient's own immune system to fight cancer through genetic modification of their own cells is rapidly emerging as a promising treatment option. Although these therapies provide great opportunities, they also pose unique challenges as investigators seek to refine the approach and expand the treatment option to more patients. A panel discussion at the AACR Annual Meeting 2013 - featuring the University of Pennsylvania physician-scientist leading the research team whose work has spurred worldwide attention to chimeric antigen receptor (CAR) technologies, and a trial participant whose leukemia remains in remission more than two and a half years after being treated with his own engineered cells - will explore the future of personalized cellular therapies.
WHERE:
AACR Annual Meeting 2013
Room 150
Walter E. Washington Convention Center
801 Mt Vernon Pl NW
Washington, DC 20001
WHEN:
Sunday, April 7, 2013
1 to 3 PM EDT
WHO:
-
Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania and the director of Translational Research in the Abramson Cancer Center
-
Douglas Olson, PhD, Penn Medicine modified T cell trial participant
Research highlights gender and age differences in eye gene therapy responses